151838-62-9

Basic information

• Product Name: N-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID
• Synonyms: 2-N-BOC-1,2,3,4-TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID;N-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID;(RS)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid, N-BOC protected;2,3(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-, 2-(1,1-dimethylethyl) ester (9CI);2,3(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-, 2-(1,1-diMethylethyl) ester;N-Boc-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;Boc-DL-Tic-OH;1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid, N-BOC protected
• CAS NO: 151838-62-9
• Molecular Formula: C₁₅H₁₉NO₄
• Molecular Weight: 277.32
• Mol File: 151838-62-9.mol

Chemical Properties

• Melting Point: 125-126
• Boiling Point: 437.6°Cat760mmHg
• Flash Point: 218.5°C
• Appearance: /
• Density: 1.222g/cm³
• Vapor Pressure: 1.97E-08mmHg at 25°C
• Refractive Index: 1.556
• Storage Temp.: 2-8°C
• PKA: 3.88±0.20(Predicted)
• CAS DataBase Reference: N-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: N-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID(151838-62-9)
• EPA Substance Registry System: N-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID(151838-62-9)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 151838-62-9(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
N-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID is used as a building block for the synthesis of novel bioactive compounds, contributing to the development of new pharmaceuticals with potential therapeutic applications.
Used in Drug Discovery:
In the field of drug discovery, N-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID serves as a valuable intermediate, facilitating the design and synthesis of innovative drug candidates with improved efficacy and selectivity.
Used in Organic Synthesis:
N-(TERT-BUTOXYCARBONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID is utilized as a key intermediate in organic synthesis, enabling the creation of complex molecular structures and the development of advanced synthetic methodologies.

InChI:InChI=1/C15H19NO4/c1-15(2,3)20-14(19)16-9-11-7-5-4-6-10(11)8-12(16)13(17)18/h4-7,12H,8-9H2,1-3H3,(H,17,18)

Upstream product

• 67123-97-1 (R,S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 41994-51-8 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid ; hydrochloride 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 551962-90-4 [1,2,3,4]-tetrahydroisoquinoline-2-carboxylic acid 
• 612-12-4 o-Xylylene dichloride 
• 143767-54-8 (R,S)-2-acetyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 22115-41-9 2-(bromomethyl)benzonitrile 
• 594838-58-1 C₂₀H₂₆N₂O₆ 
• 226924-21-6 2-tert-butoxycarbonylamino-3-(2-cyanophenyl)propionic acid 
• 143767-55-9 dimethyl 2-acetyl-1,2,3,4-tetrahydroisoquinoline-3,3-dicarboxylate 
• 594838-53-6 2-tert-butoxycarbonylamino-3-(2-cyano-phenyl)-propionic acid 2-trimethylsilanyl-ethyl ester 
• 594838-55-8 C₂₅H₃₈N₂O₆Si 

Downstream Products

• 243858-66-4 N-tert-butyloxycarbonyl-1,2,3,4-tetrahydroisoquinoline-3-methanol 
• 1263808-57-6 2-[1-(cyclohexylmethyl)piperidin-4-yl]-10,10a-dihydro-5H-imidazo[1,5-b]isoquinoline-1,3-dione 
• 1263808-55-4 2-[1-(4-fluorobenzyl)piperidin-4-yl]-10,10a-dihydro-5H-imidazo[1,5-b]isoquinoline-1,3-dione 
• 1263808-53-2 2-[1-(4-nitrobenzyl)piperidin-4-yl]-10,10a-dihydro-5H-imidazo[1,5-b]isoquinoline-1,3-dione 

Relevant articles and documents

Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-Activity relationships for (4-Arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives

Nociceptin/orphanin FQ (N/OFQ) and N/OFQ peptide (NOP) receptor are expressed and distributed in various regions such as central nervous system (CNS), peripheral nervous system, immune system, and peripheral tissues. N/OFQ and NOP receptor have important

New synthesis of tic-hydantoins sigma-1 ligands and pharmacological evaluation on cocaine-induced stimulant effects

Activation of the newly identified σ1 chaperone protein is involved in several aspects of the psychostimulant and addictive effects of cocaine. The development of ligands that selectively target the σ1 protein may lead to putative potent anti-cocaine agen

Collection of traceable compounds and uses thereof

The use of a collection of compounds of general formula (I), wherein: n is 0 or 1; p represents an integer between 1 and 6; r represents an integer between 1 and 12; R1 and R′1 represent in particular a hydrogen atom; R2 represents an amino acid side chain or an amino acid derivative; R3 represents a group derived from a carboxylic acid, bearing a basic entity; R4 represents in particular an alkyl group containing 1 to 10 carbon atoms; and A represents a hydrogen atom, a protecting group or a tracing group, in particular a fluorophor, a coloring agent or a quencher, for determining, through binding studies, ligands of receptors whose ligand is unknown or whose ligand useful for carrying out specific affinity binding assays is unknown.

Muscarinic Receptor Antagonists

This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic rece

TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF

The present invention provide a tetrahydroisoquinoline compound having a superior ACAT-inhibitory activity and/or anti-oxidation action, particularly, novel compound represented by the formula (I) (wherein each symbol is as described in the specification) and a pharmaceutically acceptable salt thereof.

TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS

This invention provides the compounds of formula (I), or its a pharmaceutically acceptable ester or amide of such compound, or a pharmaceutically acceptable salt thereof, wherein X1 is NH; R1, R2, R4 through Rs

A versatile synthesis of 2-substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepine-3-ones

A mild and general strategy for the synthesis of 2-substituted 4-amino-1,2,4,5-tetrahydro-2-benzazepine-3-ones is described. The seven-membered lactam is prepared by intramolecular amide bond formation from the intermediate amino acid, which is obtained e

CCK2 receptor antagonists containing the conformationally constrained phenylalanine derivatives, including the new amino acid Xic

The conformationally constrained analogues of phenylalanine, tetrahydroisoquinoline-3-carboxylic acid (Tic), Sic, Hic and Nic, and the new amino acid Xic have been incorporated into a potent and highly selective cholecystokinin-2 (CCK2) receptor antagonist (2) in place of the phenylalanine residue, producing compounds 15a-e. High selectivities for CCK2 over CCK1 were observed for compounds 15a-e. The in vitro profile of the analogue containing the Nic residue (15d) was identical to that of compound 2, whereas the alternative conformational constraints resulted in a significant loss of affinity. The apparent advantage of Nic in the context of these CCK2 ligands was subsequently demonstrated to be statistically significant.

Synthesis and structure-activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores

Using N-(2,6-dimethyl)phenyl-2-piperidinecarboxamide (1) and N-(α-methylbenzyl)-2-piperidinecarboxamide (2) as structural leads, a variety of analogues were synthesised and evaluated for anticonvulsant activity in the MES test in mice. In the N-benzyl series, introduction of 3-Cl, 4-Cl, 3,4-Cl2, or 3-CF3 groups on the aromatic ring led to an increase in MES activity. Replacement of the α-methyl group by either i-Pr or benzyl groups enhanced MES activity with no increase in neurotoxicity. Substitution on the piperidine ring nitrogen led to a decrease in MES activity and neurotoxicity, while reduction of the amide carbonyl led to a complete loss of activity. Movement of the carboxamide group to either the 3- or 4-positions of the piperidine ring decreased MES activity and neurotoxicity. Incorporation of the piperidine ring into a tetrahydroisoquinoline or diazahydrinone nucleus led to increased neurotoxicity. In the N-(2,6-dimethyl)phenyl series, opening of the piperidine ring between the 1- and 6-positions gave the active norleucine derivative 75 (ED50 = 5.8 mg kg-1, TD50 = 36.4 mg kg-1, PI = 6.3). Replacement of the piperidine ring of 1 by cycloalkane (cyclohexane, cyclopentane, and cyclobutane) resulted in compounds with decreased MES activity and neurotoxicity, whereas replacement of the piperidine ring by a 4-pyridyl group led to a retention of MES activity with a comparable PI. Simplification of the 2-piperidinecarboxamide nucleus of 1 into a glycinecarboxamide nucleus led to about a six-fold decrease in MES activity. The 2,6-dimethylanilides were the most potent compounds in the MES test in each group of compounds evaluated, and compounds 50 and 75 should be useful leads in the development of agents for the treatment of tonic-clonic and partial seizures in man.

Boronic ester and acid compounds, synthesis and uses

Disclosed herein are boronic ester and acid compounds, their synthesis and uses. More specifically, disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds.